Avastin vs eylea: which eye drug needs fewer shots?

NCT ID NCT04101877

Ongoing Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two drugs, Avastin and Eylea, given as eye injections for wet age-related macular degeneration (AMD). The main goal is to see which drug requires fewer injections over two years while still controlling the disease. Researchers will also check vision, eye thickness, and quality of life. About 402 people aged 50 and older with wet AMD are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) and aflibercept (Eylea)
What this could lead to: If it works, this could show which drug is more cost-effective and requires fewer injections for wet AMD, improving patient convenience and reducing treatment burden.
What could go wrong: This is a Phase 2 trial, so results are still early. The drugs may work similarly, or one might not be as effective as hoped. Risks include eye infection or inflammation from injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology

Mölndal, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.